US5631365A
(en)
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5824683A
(en)
*
|
1995-11-28 |
1998-10-20 |
Schering Corporation |
2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
|
ZA969888B
(en)
*
|
1995-11-28 |
1997-05-26 |
Schering Corp |
2'-[[4'-halo-[1,1-biphenyl]-4-yl]methyl]-5'-methyl-spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-ones
|
US6410584B1
(en)
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
US6200771B1
(en)
|
1998-10-15 |
2001-03-13 |
Cell Pathways, Inc. |
Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
|
US6133271A
(en)
*
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
US6369092B1
(en)
|
1998-11-23 |
2002-04-09 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted benzimidazole derivatives
|
US6034099A
(en)
*
|
1998-11-24 |
2000-03-07 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
|
US6077842A
(en)
*
|
1998-11-24 |
2000-06-20 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
US6025394A
(en)
|
1999-01-29 |
2000-02-15 |
Cell Pathways, Inc. |
Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
|
US6020379A
(en)
*
|
1999-02-19 |
2000-02-01 |
Cell Pathways, Inc. |
Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
|
US6403799B1
(en)
*
|
1999-10-21 |
2002-06-11 |
Agouron Pharmaceuticals, Inc. |
Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
|
US6821978B2
(en)
*
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
EP1790652A1
(en)
*
|
2001-08-28 |
2007-05-30 |
Schering Corporation |
Polycyclic guanine phosphodiesterase V inhibitors
|
AR036674A1
(es)
*
|
2001-08-28 |
2004-09-29 |
Schering Corp |
Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos
|
JP2005511500A
(ja)
*
|
2001-08-31 |
2005-04-28 |
ザ ロックフェラー ユニバーシティー |
脳におけるホスホジエステラーゼ活性およびホスホジエステラーゼ1b媒介シグナル伝達の調節
|
JP2005509038A
(ja)
|
2001-11-09 |
2005-04-07 |
シェーリング コーポレイション |
多環式グアニン誘導体ホスホジエステラーゼv阻害剤
|
SI1509525T1
(sl)
|
2002-05-31 |
2006-12-31 |
Schering Corp |
Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
|
MXPA06001195A
(es)
*
|
2003-07-31 |
2006-04-11 |
Schering Corp |
Metabolito de inhibidor de xantina fosfodiesterasa 5 y derivados del mismo utiles para el tratamiento de la disfuncion erectil.
|
AU2004292991A1
(en)
*
|
2003-11-21 |
2005-06-09 |
Schering Corporation |
Phosphodiesterase v inhibitor formulations
|
SE0401653D0
(sv)
*
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
New compounds
|
US20070004745A1
(en)
*
|
2005-03-25 |
2007-01-04 |
Schering-Plough Corporation |
Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
|
WO2006133261A2
(en)
|
2005-06-06 |
2006-12-14 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
EP1919287A4
(en)
*
|
2005-08-23 |
2010-04-28 |
Intra Cellular Therapies Inc |
ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
|
EP1968947A1
(en)
|
2005-12-23 |
2008-09-17 |
AstraZeneca AB |
Gaba-b receptor modulators
|
KR20080091452A
(ko)
|
2005-12-23 |
2008-10-13 |
아스트라제네카 아베 |
위장 장애의 치료를 위한 이미다졸 유도체
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
US9255099B2
(en)
*
|
2006-06-06 |
2016-02-09 |
Intra-Cellular Therapies, Inc. |
Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors
|
WO2008063505A1
(en)
|
2006-11-13 |
2008-05-29 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US9006258B2
(en)
*
|
2006-12-05 |
2015-04-14 |
Intra-Cellular Therapies, Inc. |
Method of treating female sexual dysfunction with a PDE1 inhibitor
|
US7901872B2
(en)
|
2007-05-21 |
2011-03-08 |
Macronix International Co., Ltd. |
Exposure process and photomask set used therein
|
EP2170896A2
(en)
*
|
2007-06-21 |
2010-04-07 |
Schering Corporation |
Polycyclic guanine derivatives and use thereof
|
CN104370920A
(zh)
|
2007-12-06 |
2015-02-25 |
武田药品工业株式会社 |
有机化合物
|
JP5701608B2
(ja)
*
|
2007-12-06 |
2015-04-15 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
WO2009144548A1
(en)
*
|
2008-05-28 |
2009-12-03 |
Glenmark Pharmaceuticals S.A. |
Imidazo [2,1-b] purine derivatives as trpa1 modulators
|
CA3000973A1
(en)
|
2008-06-10 |
2009-12-17 |
Abbvie Inc. |
Tricyclic compounds
|
SG171774A1
(en)
*
|
2008-12-06 |
2011-07-28 |
Intra Cellular Therapies Inc |
Organic compounds
|
CA2740394A1
(en)
|
2008-12-06 |
2010-06-10 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
SG171777A1
(en)
|
2008-12-06 |
2011-07-28 |
Intra Cellular Therapies Inc |
Organic compounds
|
GEP20146029B
(en)
|
2008-12-06 |
2014-02-10 |
Intracellular Therapies Inc |
Organic compounds
|
CN102231953A
(zh)
|
2008-12-06 |
2011-11-02 |
细胞内治疗公司 |
有机化合物
|
EP2367428B1
(en)
|
2008-12-06 |
2016-04-06 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
JP2012518685A
(ja)
|
2009-02-25 |
2012-08-16 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
眼障害のためのpde1阻害剤
|
EP2434895A4
(en)
|
2009-05-13 |
2013-08-07 |
Intra Cellular Therapies Inc |
ORGANIC CONNECTIONS
|
WO2011016861A2
(en)
|
2009-08-05 |
2011-02-10 |
Intra-Cellular Therapies, Inc. |
Novel regulatory proteins and inhibitors
|
PL2506716T3
(pl)
|
2009-12-01 |
2017-10-31 |
Abbvie Inc |
Nowe związki tricykliczne
|
MX2012006381A
(es)
|
2009-12-01 |
2012-06-19 |
Abbott Lab |
Nuevos compuestos triciclicos.
|
US9434730B2
(en)
|
2010-05-31 |
2016-09-06 |
Intra-Cellular Therapies, Inc. |
PDE1 inhibitor compounds
|
EP2590657A4
(en)
|
2010-05-31 |
2014-02-12 |
Intra Cellular Therapies Inc |
ORGANIC COMPOUNDS
|
US9763948B2
(en)
|
2010-05-31 |
2017-09-19 |
Intra-Cellular Therapies, Inc. |
PDE1 inhibitory compounds and methods
|
TW201206937A
(en)
|
2010-05-31 |
2012-02-16 |
Intra Cellular Therapies Inc |
Organic compounds
|
JP6051210B2
(ja)
|
2011-06-10 |
2016-12-27 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
JP6549040B2
(ja)
|
2013-02-17 |
2019-07-24 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
新規使用
|
ES2717688T3
(es)
|
2013-03-15 |
2019-06-24 |
Intra Cellular Therapies Inc |
Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
|
JP6437519B2
(ja)
|
2013-03-15 |
2018-12-12 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
JP6696904B2
(ja)
|
2014-01-08 |
2020-05-20 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
製剤および医薬組成物
|
JP6810613B2
(ja)
|
2014-06-20 |
2021-01-06 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
JP6591530B2
(ja)
|
2014-08-07 |
2019-10-16 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
US9546175B2
(en)
|
2014-08-07 |
2017-01-17 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
JP6596080B2
(ja)
|
2014-09-17 |
2019-10-23 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
化合物および方法
|
BR112017012005B1
(pt)
|
2014-12-06 |
2023-04-04 |
Intra-Cellular Therapies, Inc |
Compostos orgânicos inibidores de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
|
WO2016090380A1
(en)
|
2014-12-06 |
2016-06-09 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
SG10201913999PA
(en)
|
2015-10-16 |
2020-03-30 |
Abbvie Inc |
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
|
US11780848B2
(en)
|
2015-10-16 |
2023-10-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US10682354B2
(en)
|
2016-03-28 |
2020-06-16 |
Intra-Cellular Therapies, Inc. |
Compositions and methods
|
EP3970719A1
(en)
|
2016-09-12 |
2022-03-23 |
Intra-Cellular Therapies, Inc. |
Pde1 inhibitor for use in a method of treatment or prophylaxis of inflammation and/or an inflammatory disease or disorder
|
WO2018125810A1
(en)
|
2016-12-28 |
2018-07-05 |
Dart Neuroscience, Llc |
Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
|
US11434247B1
(en)
|
2017-11-27 |
2022-09-06 |
Dart Neuroscience Llc |
Substituted furanopyrimidine compounds as PDE1 inhibitors
|
US11839614B2
(en)
|
2018-01-31 |
2023-12-12 |
Intra-Cellular Therapies, Inc. |
Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
|